ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,493.70
0.55%
S&P ASX All Technology
3,942.30
0.62%
Brent Oil
75.46
-0.61%
US Dollar vs AUD
1.60733
0.28%
Bitcoin
105,290.11
1.50%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Arcus Biosciences Inc (RCUS) Share Price

Arcus Biosciences Inc

Arcus Biosciences Inc (RCUS)

NYSE
13.01
-0.08
(-0.61%)
Closed 30 January 8:00AM
Delayed by 15 minutes
13.01
0.00
(0.00%)
After Hours: 9:33AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
13.01
Bid
-
Offer
-
Volume
482,362
12.83 Day's Range 13.32
12.97 52 Week Range 20.31
Market Cap
1.191B
Previous Close
13.09
Open
13.07
Last Trade
70632
@
13.01
Last Trade Time
Financial Volume
US$ 6,289,412
VWAP
13.0388
Average Volume (3m)
703,892
Shares Outstanding
91,511,609
Dividend Yield
-
PE Ratio
-3.88
Earnings Per Share (EPS)
-3.35
Revenue
117M
Net Profit
-307M

About Arcus Biosciences Inc

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arcusbio.com
Headquarters
Camden, Delaware, USA
Founded
-
Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was US$13.09. Over the last year, Arcus Biosciences shares have traded in a share price range of US$ 12.97 to US$ 20.31.

Arcus Biosciences currently has 91,511,609 shares in issue. The market capitalisation of Arcus Biosciences is US$1.20 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -3.88.

Ask ADVFN Intelligence (AI)

RCUS Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

28 January 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

28 January 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

28 January 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

28 January 2025
Edgar (US Regulatory)

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

25 January 2025
Business Wire

Form 8-K - Current report

22 January 2025
Edgar (US Regulatory)

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc...

22 January 2025
Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

25 December 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

21 December 2024
Edgar (US Regulatory)

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

20 December 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.04-7.4021352313214.0514.1112.9776742813.29507962CS
4-2.17-14.295125164715.1815.61512.9761009314.08967656CS
12-3.37-20.573870573916.3818.9812.9770389215.56972838CS
26-2.84-17.917981072615.8518.9812.9767711116.11433232CS
52-2.09-13.841059602615.120.3112.9771417316.3759393CS
156-16.71-56.224764468429.7239.7512.9586832321.06763563CS
2603.3634.81865284979.6549.18.5575814123.6907783CS

RCUS - Frequently Asked Questions (FAQ)

What is the current Arcus Biosciences share price?
The current share price of Arcus Biosciences is US$ 13.01
How many Arcus Biosciences shares are in issue?
Arcus Biosciences has 91,511,609 shares in issue
What is the market cap of Arcus Biosciences?
The market capitalisation of Arcus Biosciences is USD 1.2B
What is the 1 year trading range for Arcus Biosciences share price?
Arcus Biosciences has traded in the range of US$ 12.97 to US$ 20.31 during the past year
What is the PE ratio of Arcus Biosciences?
The price to earnings ratio of Arcus Biosciences is -3.88
What is the cash to sales ratio of Arcus Biosciences?
The cash to sales ratio of Arcus Biosciences is 10.18
What is the reporting currency for Arcus Biosciences?
Arcus Biosciences reports financial results in USD
What is the latest annual turnover for Arcus Biosciences?
The latest annual turnover of Arcus Biosciences is USD 117M
What is the latest annual profit for Arcus Biosciences?
The latest annual profit of Arcus Biosciences is USD -307M
What is the registered address of Arcus Biosciences?
The registered address for Arcus Biosciences is 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934
What is the Arcus Biosciences website address?
The website address for Arcus Biosciences is www.arcusbio.com
Which industry sector does Arcus Biosciences operate in?
Arcus Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PACKRanpak Holdings Corp
US$ 8.45
(47.21%)
14.75M
EATBrinker International Inc
US$ 179.80
(16.29%)
4.41M
SHCOSoho House and Co Inc
US$ 8.30
(12.62%)
3.69M
NEXANexa Resources SA
US$ 6.30
(9.95%)
45.11k
BEBloom Energy Corporation
US$ 22.38
(9.71%)
9.9M
BKKTBakkt Holdings Inc
US$ 18.90
(-28.30%)
1.89M
LCLendingClub Corporation
US$ 14.42
(-14.32%)
11.16M
TEVATeva Pharmaceutical Industries Ltd
US$ 18.54
(-13.89%)
41.97M
SRFMSurf Air Mobility Inc
US$ 4.24
(-13.82%)
383.57k
NEPNextEra Energy Partners LP
US$ 10.505
(-11.20%)
14.8M
BABAAlibaba Group Holding Limited
US$ 96.715
(0.71%)
75.4M
FFord Motor Company
US$ 10.20
(1.19%)
69.85M
ABEVAmbev SA
US$ 1.82
(-1.62%)
47.63M
TEVATeva Pharmaceutical Industries Ltd
US$ 18.54
(-13.89%)
41.97M
QBTSD Wave Quantum Inc
US$ 5.52
(-3.83%)
41.67M

RCUS Discussion

View Posts
Monksdream Monksdream 4 months ago
RCUS a buy under $14
👍️0
PennyWorld PennyWorld 1 year ago
https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?ref=biztoc.com
👍️0
conix conix 3 years ago
Biotechs are starting to react to news...finally.
👍️0
dinogreeves dinogreeves 5 years ago
The stock didn't react as well as expected with the partnership, but it did hi almost my price target. This is a partnership 200 million equity investment and 175 million up front payment, which. implies no offering on the table. Makes you wonder why the stock is down, guess people were expecting a buyout. Some of these people are so lame, unbelievable.
👍️0
lovetc lovetc 5 years ago
Also in the DEF 14.....didnt see any information regarding Gilead....
👍️0
lovetc lovetc 5 years ago
shorted some and bought some put at $31 last Friday....Also today when it reached $30 I short.....I find no reason not to short above $30 lol....It will be $18 soon since the Volumn start declined....
👍️0
dinogreeves dinogreeves 5 years ago
RCUS will likely hit 40 this week and if it does that could essentially mean that there is buyout looming from GI*LD. Someone is buying heavy between 27-29 dollars, obviously they don't want it dip more than 26-27 dollars, it could be a number of reasons that is beyond any retails control.
👍️0
dinogreeves dinogreeves 5 years ago
Bought another 1000 shares on that dip, going to wait this one.
👍️0
dinogreeves dinogreeves 5 years ago
Possible huge asset buy, or outright buyout coming from GILD or even a partnership.
👍️0
dinogreeves dinogreeves 5 years ago
RCUS getting ready to pop to 33-35 dollars.
👍️0
dinogreeves dinogreeves 5 years ago
This is my letter to the shorts with margin account


That is where dummies like you are mistaken. If GILD places anywhere close to that dollar amount this stock jumps over triple digits in less then 2 hours and if there is buyout it won't even let you blink, just one share will it to the buyout price. If GOOGLE has 17% stake on this company and GILD is looking to either buy or take a stake, there must be something that you and I are not aware of the current directors sold their pervious company to Bristol for 1.5 billion dollars. There is more here than meets the eye. I am taking my chance because if no balls no glory and when that happens short margin account will be vaporized.


https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 years ago
If this happens the stock will shoot up to over $200 dollars in an instant. Only if that happens.



https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 years ago
News could come from GI*LD that there is a buyout. Watch for news.
👍️0

Your Recent History

NYSE
RCUS
Arcus Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads